They have just started enrolling patients recently

They have just started enrolling patients recently, long ways to go.

Generex Biotechnology Announces First Patient Enrolled in the Phase II Clinical Trial of
AE37 in Combination with Pembrolizumab (Keytruda) for the Treatment of Triple
Negative Breast Cancer
MIRAMAR, FL, Sept 17, 2019/PRNewswire/ Generex Biotechnology Corporation
(www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote)
today announced that the NSABP Foundation, Inc. (NSABP) has enrolled the first patient
in the study: A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37
Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer (NSABP FB-14).
The trial, conducted in conjunction with research partners Merck and the NSABP
Foundation, is designed to evaluate the safety and tolerability of AE37 given in
combination with KEYTRUDA (pembrolizumab) as well as the objective response rate.
Eric von Hofe, President of NuGenerex-ImmunoOncology commented, “This is an exciting
milestone for NuGenerex Immuno-Oncology, as we have now revitalized our AE37
development program with a focus on combination therapy with checkpoint inhibitors,
which are now becoming standard of care for a broad array of cancers. Combining our
promising immunotherapeutic with Merck’s checkpoint inhibitor, KEYTRUDA for the
treatment of triple negative breast cancer represents a novel treatment strategy for a
cancer of high unmet need. Prior studies with each agent alone showed promising signs
of efficacy. By combining the mechanisms of checkpoint inhibition by KEYTRUDA with the
robust, long-lasting and tumor-specific T-cell activation by AE37, we hope to enhance the
clinical effectiveness of the immunotherapy strategies.”